Brief: Results From Phase 2 Clinical Trial Of Bermekimab In The Treatment Of Atopic Dermatitis

XBiotech

01/03/2019 18:44

March 1 (Reuters) - XBiotech Inc  XBIT.O :
    * BREAKTHROUGH RESULTS FROM PHASE 2 CLINICAL TRIAL OF
BERMEKIMAB
IN THE TREATMENT OF ATOPIC DERMATITIS (AD) TO BE PRESENTED ON
MARCH 2, 2019 AT AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING
    * XBIOTECH - RAPID,SIGNIFICANT REDUCTION IN SKIN LESIONS,
66%
(P<0.001) AND 76% (P<0.001) MEAN REDUCTION IN EASI SCORE IN 4
AND 7 WEEKS, RESPECTIVELY.
    * XBIOTECH INC - SUBSTANTIAL MEAN REDUCTION OF WORST ITCH
AND PAIN
71% (P<0.001) AND 84% (P<0.001) WITHIN 7 WEEKS, RESPECTIVELY.
    * XBIOTECH INC - RAPID AND SIGNIFICANT RESOLUTION OF WORST
ITCH
AND PAIN, 57% (P<0.001) AND 61% (P<0.001) MEAN REDUCTION WITHIN
4 WEEKS, RESPECTIVELY.

Source text for Eikon:  ID:nGNX6kjlYJ 
Further company coverage:  XBIT.O 

 ((Reuters.Briefs@thomsonreuters.com;))